What Cancers Can Be Treated With CAR-T Cell Therapy?

CAR-T cell therapy is one of the most talked-about advances in cancer treatment, and that attention brings a common question: does it work for my cancer?

The honest answer is that it works remarkably well for some cancers and, so far, not for others. The reason has less to do with how aggressive a cancer is and more to do with a technical detail — whether the cancer cells carry a marker the engineered cells can reliably find.

This article explains which cancers CAR-T cell therapy currently treats, why blood cancers respond while solid tumours remain difficult, and what options exist when this approach is not suitable.

In this article

• The short answer


• Blood cancers treated with CAR-T


• Why solid tumours are harder


• What determines whether you are eligible


• If CAR-T is not an option


• Frequently asked questions


• Getting your case reviewed

The short answer

CAR-T cell therapy is established for cancers that arise from B-cells and plasma cells — in other words, certain lymphomas, leukaemias and myeloma. It is generally used after other treatments have been tried and the disease has returned or stopped responding.

For solid tumours — breast, lung, colon, pancreatic and most others — CAR-T is not standard treatment. Research continues, but the obstacles are real and not yet solved.

Blood cancers treated with CAR-T

The engineered cells need a target: a protein on the cancer cell's surface that healthy tissue does not carry in large amounts. In B-cell cancers that target is usually CD19, and in myeloma it is usually BCMA.

The cancers where CAR-T cell therapy is used include:

Diffuse large B-cell lymphoma (DLBCL). An aggressive lymphoma, and one of the first diseases where this approach was approved. It is typically considered after relapse.

Follicular lymphoma. A slow-growing lymphoma that tends to return repeatedly. CAR-T is considered after two or more previous lines of treatment. We cover this in detail in our article on CAR-T cell therapy for follicular lymphoma.

Mantle cell lymphoma. An uncommon lymphoma that often responds initially to treatment and then relapses.

Marginal zone lymphoma. Another indolent B-cell lymphoma treated in the relapsed setting.

B-cell acute lymphoblastic leukaemia (ALL). Particularly in children and younger adults, where CAR-T has become an important option after relapse.

Chronic lymphocytic leukaemia (CLL). Used in selected patients whose disease has progressed through other therapies.

Multiple myeloma. Here the target is BCMA rather than CD19, but the principle is the same.

What unites this list is not the aggressiveness of the disease. It is that all of these cancers grow from cells that carry a consistent, identifiable surface marker.

Why solid tumours are harder

If the approach works so well in blood cancers, why not in breast or lung cancer? Three obstacles stand in the way.

Finding a safe target. Solid tumours rarely carry a protein that healthy organs do not also carry. An engineered cell that attacks that protein would attack healthy tissue too. In B-cell cancers the trade-off is acceptable — losing healthy B-cells is manageable. Losing healthy lung or liver tissue is not.

Physically reaching the tumour. Blood cancers circulate, so the modified cells meet them naturally. A solid tumour is a dense mass with its own abnormal blood supply, and engineered cells often struggle to get inside it.

Surviving once inside. The environment around a solid tumour actively suppresses immune cells. Even cells that reach the tumour may be switched off before they can do their work.

These are engineering problems, and research is addressing all three. But they are the reason CAR-T cell treatment is not currently offered for most solid tumours outside clinical trials.

What determines whether you are eligible

Having a cancer on the list above does not by itself mean CAR-T cell therapy is appropriate. Assessment usually considers:

• Which treatments you have already had. CAR-T is generally reserved for disease that has relapsed or become refractory after previous lines of therapy.


• Confirmation of the target. Testing establishes whether the cancer cells carry CD19 or BCMA.


• Organ function. Heart, lung, kidney and liver function need to be adequate to tolerate the process and manage possible side effects.


• Overall fitness. The journey takes several weeks and includes a period of close monitoring.


• Disease control during manufacturing. Cells take weeks to produce; the disease must be manageable in the meantime.

If CAR-T is not an option

For solid tumours, a different form of cellular therapy may apply. TIL therapy uses tumour-infiltrating lymphocytes — immune cells taken from inside the tumour itself, expanded in a laboratory and returned to the patient. Because these cells already recognise the tumour, the targeting problem is approached from the opposite direction.

TIL therapy has been used most in metastatic melanoma, with ongoing work in other solid tumours.

Getting your case reviewed

Whether CAR-T cell therapy applies to your situation depends on your diagnosis, your treatment history and your current health — details that need to be reviewed together rather than judged from a list.

If you would like an assessment, you can contact our team and we will explain which records are needed to begin.

This article is general information about cancer types and CAR-T cell therapy. It is not medical advice and does not replace consultation with a qualified physician.